Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Total Non-current Liabilities
All obligations due after more than one year.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 6.0% from a year ago
Total non-current liabilities stood at $234.17M at the end of Q1 FY2026, down 6.0% from a year earlier and down 5.1% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Total non-current liabilities amounted to 105.4% of total assets at the end of Q1 FY2026, up 9.1 pp from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -6.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 246.87M USD
- Year-over-year change
- -6.0%
- 4-year CAGR
- -9.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 246.87M | -6.0% |
| FY2024 | 2024-12-31 | 262.52M | -13.8% |
| FY2023 | 2023-12-31 | 304.67M | -12.8% |
| FY2022 | 2022-12-31 | 349.57M | -6.6% |
| FY2021 | 2021-12-31 | 374.21M | — |
Total Non-current Liabilities vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's Mar 2026 total non-current liabilities of $234.17M is the 2nd highest of the 11 companies compared; the peer median is $18.43M.
- Its year-over-year change of -6.0% is the 3rd highest of 9, against a peer median of -13.9%.
- Total non-current liabilities amounts to 105.4% of total assets for FHTX, versus a peer median of 6.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.32B | +88832.8% | -8.4% | 1.5% | |
| Mar 2026 | $234.17M | -6.0% | -10.9% | 105.4% | |
| Mar 2026 | $151.67M | -17.3% | +78.5% | 48.2% | |
| Mar 2026 | $82.75M | -22.3% | +11.9% | 74.8% | |
| Mar 2026 | $45.47M | -10.5% | +38.7% | 13.6% | |
| Mar 2026 | $19.68M | -59.5% | -26.8% | 8.0% | |
| Mar 2026 | $17.18M | +3.5% | +2.1% | 4.0% | |
| Mar 2026 | $16.5M | -10.0% | -3.5% | 25.7% | |
| Mar 2026 | $1.9M | -92.5% | -10.1% | 0.8% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | — | — | 0.0% |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding FHTX) | $18.43M | -13.9% | -0.7% | 6.0% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 101.14M | 52.21M | 80.34M | 55.45M | 80.88M |
| Short-term Investments | 53.15M | 293.58M | 153.72M | 188.29M | 78.02M |
| Net Receivables | 300M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.6M | 6.12M | 5.85M | 4.34M |
| Total Current Assets | 459.56M | 351.4M | 240.18M | 249.6M | 163.24M |
| Property, Plant & Equipment (Net) | 56.08M | 49.4M | 42.91M | 32.61M | 32.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.13M | 4.09M | 2.82M | 1.78M | 2M |
| Total Non-current Assets | 60.21M | 53.48M | 45.74M | 34.38M | 34.87M |
| Total Assets | 519.77M | 404.88M | 285.92M | 283.98M | 198.1M |
| Account Payables | 3.82M | 5.41M | 6.26M | 3.79M | 4.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 674K | 0 | 0 |
| Deferred Revenue | 28.32M | 32.82M | 34.55M | 45.61M | 43.19M |
| Other Current Liabilities | 5.99M | 5.06M | 4.38M | 4.74M | 6.32M |
| Total Current Liabilities | 48.69M | 55.21M | 58.44M | 66.99M | 59.74M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 322.73M | 304M | 268.12M | 234.46M | 205.96M |
| Other Non-current Liabilities | 143K | 29K | 0 | 0 | 556K |
| Total Non-current Liabilities | 374.21M | 349.57M | 304.67M | 262.52M | 246.87M |
| Total Liabilities | 422.9M | 404.77M | 363.11M | 329.51M | 306.6M |
| Common Stock | 4K | 4K | 4K | 6K | 6K |
| Retained Earnings | (264.26M) | (373.14M) | (471.56M) | (558.18M) | (632.47M) |
| Accumulated OCI | (10K) | (3.99M) | (826K) | 135K | 24K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 96.87M | 112K | (77.19M) | (45.53M) | (108.5M) |
| Total Debt | 58.33M | 51.51M | 45.07M | 37.13M | 41.27M |
| Net Debt | (42.8M) | (707K) | (35.26M) | (18.32M) | (39.61M) |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.